Regulatory Affairs Services Provider in Qatar
DDReg provides regulatory affairs services in Qatar for pharmaceutical, medical device, biologics, and health product companies. Our consultants manage MoPH registration submissions through the Pharmacy and Drug Control Department (PDCD), coordinate GCC fast-track procedures, and maintain post-registration compliance across Qatar's life sciences market.
Qatar's Regulatory Framework for Medicines and Medical Devices
The Ministry of Public Health (MoPH) is the sole regulatory authority in Qatar with responsibility for pharmaceutical product registration, import licensing, pharmacy oversight, and post-market surveillance. Within MoPH, the Pharmacy and Drug Control Department (PDCD) administers all product registration activities: it reviews dossiers, evaluates applications, coordinates the registration committee process, and issues marketing authorisations.
Qatar operates as a member of the Gulf Cooperation Council (GCC) and participates in GCC harmonisation frameworks for pharmaceuticals and medical devices. The GCC Drug Registration system enables centrally registered products to receive expedited review in Qatar under the GCC fast-track pathway. Qatar's pharmaceutical market is import-dependent, and domestic manufacturing capacity is limited. This means MoPH regulatory approval is the primary gateway to commercial supply for all foreign manufacturers.
In 2016, the Supreme Council of Health was disbanded and its regulatory functions transferred back to MoPH. Qatar National Vision 2030 and successive National Health Strategies have driven significant investment in healthcare infrastructure and capacity. This creates ongoing demand for medicines, medical devices, and advanced therapies across Hamad Medical Corporation (HMC) and the private healthcare sector.
Regulatory Authorities in Qatar
| Authority | Role |
|---|---|
| MoPH (Ministry of Public Health) | Overall regulatory authority; policy, licensing, and enforcement oversight for all health products and pharmaceutical facilities |
| PDCD (Pharmacy and Drug Control Department) | Operational registration authority; administers the PDCD E-system; manages dossier submission, assessment, and registration committee decisions |
| GCC-DR (GCC Drug Registration) | Regional harmonisation body: centrally registered GCC products qualify for Qatar fast-track assessment; coordinates pharmaceutical standards across Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and UAE |
| HMC (Hamad Medical Corporation) | Primary public hospital network and key institutional customer; formulary listing distinct from MoPH registration |
Regulatory Consulting in Qatar - Services Portfolio
DDReg's pharmaceutical regulatory services in Qatar cover the full product lifecycle across medicines, medical devices, biologics, and in vitro diagnostics.
-
Pharmaceutical Registration - New Applications
-
Medical Device Registration and Import Licensing
-
Post-Registration Lifecycle Management
-
Regulatory Strategy and Intelligence
MoPH Registration Services in Qatar - Submission Process
DDReg manages Qatar eCTD regulatory submissions through structured phases:
-
Pre-Submission Preparation
-
Dossier Preparation
-
PDCD E-System Submission and Validation
-
Technical Assessment and Registration Committee
-
Registration Certificate and Post-Approval
Qatar Regulatory Approval Timelines
Timelines depend on submission completeness, dossier quality, and PDCD workload. The four-month response window for additional information requests is strictly enforced:
| Product / Procedure | Typical Timeline |
|---|---|
| New pharmaceutical (standard NDA) | 6–12 months from validated submission |
| Generic pharmaceutical | 4–9 months (bioequivalence data complete) |
| GCC fast-track pharmaceutical | 2–4 months (subject to PDCD discretion) |
| Biologic / biosimilar | 9–18 months |
| Medical device (Class A–B) | 3–6 months (import permit per shipment) |
| Medical device (Class C–D) | 6–9 months |
| IVD (all classes) | 4–8 months |
| Registration renewal | 2–4 months (documentation current) |
| Variation (minor) | 1–3 months |
| Variation (major) | 3–6 months |
DDReg's Expertise in Regulatory Support in Qatar
Our consultants understand the PDCD E-system appointment-based submission workflow - the initial administrative review, eCTD virus scan validation, appointment attendance requirements, and the four-month hard deadline for additional information responses. This process knowledge prevents procedural rejections unrelated to product quality or data.
Qatar's GCC fast-track pathway offers significant timeline reduction for products holding a valid GCC central registration certificate. DDReg assesses GCC fast-track eligibility at project outset and coordinates GCC registration strategy for companies planning multi-GCC market entry, so that Qatar registration benefits from expedited review where conditions are met.
Foreign manufacturers cannot submit directly to MoPH. All interactions — dossier submission, additional information responses, and committee communications — occur through a locally registered Qatari AR. DDReg coordinates AR selection and briefing, prepares all submission documentation, and manages AR communications with PDCD throughout the registration process.
Qatar requires Arabic labelling and consumer-facing documentation. DDReg provides Arabic-language regulatory writing for product labels, package inserts, and patient information ensuring regulatory terminology accuracy beyond standard translation services.
Qatar's medical device framework operates through per-shipment import permits rather than a standing product registration. DDReg manages permit applications on a shipment basis, maintains reference market approval documentation, and coordinates customs clearance timing ensuring supply continuity without permit gaps.
Global Reach Explorer
Find Your Solution
Our Regulatory Affairs Consulting Services in Qatar portfolio covers:
Regulatory Strategies
The pharmaceutical industry operates under stringent regulations to ensure the safety, efficacy, and quality...
New Product Marketing Authorizations
Navigating marketing authorization is a complex and time-sensitive process. Every country has its own regulatory framework...
Gap Analysis and Remediation
In the highly regulated pharmaceutical industry, maintaining compliance is critical. Regulatory gap analysis helps identify deficiencies in technical documentation...
Regulatory Due Diligence
Regulatory issues arise unexpectedly and can create significant strain on a company’s resources. As such, it is advisable for all companies to carry out regular and frequent regulatory due diligence and audits...
API & DMF services
Drug Master Files (DMFs) contain confidential and detailed information regarding API processes—from manufacturing to storage. DDReg’s DMF Services deliver precise...
CMC Advisory
DDReg’s CMC services are dedicated to assisting customers in developing robust and an efficient regulatory strategy through all development phases - authoring...
Post Approval Life Cycle Management
Maximize product value with expert pharma lifecycle management. Our dedicated team ensures that your product remains on shelves and compliant with ever-evolving regulations through strategic post-approval management...
Certification Services
Partner with DDReg to navigate the complex process of regulatory certification of pharmaceutical...
ANDA and MA Holder Services
Our comprehensive services support both Abbreviated New Drug Applications (ANDA) and Marketing Authorization processes.
Publishing & Submission
Our comprehensive digital solution transforms traditional paper dossier submissions into a streamlined electronic format. With robust infrastructure and cutting‐edge management processes...
